Plain-English translation of NCT06666634 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tested ICG-99mTc-nanoscan, a new imaging tracer designed to help doctors identify cancer-affected lymph nodes before surgery. Researchers gave patients two injections—one with a standard tracer and one with the new hybrid tracer—and compared how well each one lit up the lymph nodes on imaging scans. The goal was to confirm that the new tracer works just as well as the current standard, so patients would continue to receive high-quality care.
When patients with melanoma, oral cancer, or penile cancer need surgery, doctors use special imaging to find the first lymph nodes where cancer might have spread. This trial was designed to make sure the new hybrid tracer is just as effective and safe as the older method, so the standard of care wouldn't decrease if hospitals switched to using it.
Participants received two injections as part of their surgical preparation—first a standard radioactive tracer injection, then the new hybrid tracer injection. Both injections used doses consistent with routine clinical care. Doctors then used imaging scans to compare how well each tracer identified the lymph nodes involved with cancer, and measured the signal strength during surgery to make sure the new tracer performed the same way as the standard method.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Netherlands
Sponsor
The Netherlands Cancer Institute
Enrollment target
~29 participants
Started
April 2023
Primary completion
July 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.